# FDA Commissioner Statements on Compounded Peptides

Canonical source: https://retacompare.com/research/fda-commissioner-statements-71

FDA · 2026-03-12


    FDA leadership has addressed compounded peptide issues in multiple public statements through 2025 and into 2026. The Commissioner's remarks at the FDA Science Board meeting in January 2026 emphasized that compounded drugs serve a legitimate role in American healthcare but that the compounded GLP-1 market had grown in ways inconsistent with the statutory framework. The Commissioner reiterated FDA's commitment to enforcement discretion for genuine patient-specific needs while rejecting the interpretation that enforcement discretion could substitute for lawful approval pathways. These statements have been cited in subsequent litigation and congressional testimony.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources